NASDAQ:CNCE Concert Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Concert Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.93 -0.32 (-3.46 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$8.69Now: $8.93▼$9.4250-Day Range$9.08MA: $9.85▼$10.8252-Week Range$5.36Now: $8.93▼$13.09Volume182,123 shsAverage Volume155,519 shsMarket Capitalization$265.02 millionP/E RatioN/ADividend YieldN/ABeta0.85 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingConcert Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.50, Concert Pharmaceuticals has a forecasted upside of 118.4% from its current price of $8.93.Amount of Analyst CoverageConcert Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesConcert Pharmaceuticals has received 496 “outperform” votes. (Add your “outperform” vote.)Underperform VotesConcert Pharmaceuticals has received 418 “underperform” votes. (Add your “underperform” vote.)Community SentimentConcert Pharmaceuticals has received 54.27% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNCE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldConcert Pharmaceuticals does not currently pay a dividend.Dividend GrowthConcert Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Concert Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.00% of the stock of Concert Pharmaceuticals is held by insiders.Percentage Held by Institutions72.43% of the stock of Concert Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Concert Pharmaceuticals are expected to decrease in the coming year, from ($2.65) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Concert Pharmaceuticals is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Concert Pharmaceuticals is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConcert Pharmaceuticals has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNCE Previous Symbol CUSIPN/A CIK1367920 Webwww.concertpharma.com Phone781-860-0045Debt Debt-to-Equity RatioN/A Current Ratio16.07 Quick Ratio16.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.08 million Price / Sales245.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.26 per share Price / Book2.10Profitability EPS (Most Recent Fiscal Year)($3.29) Net Income$-78,170,000.00 Net Margins-1,108.62% Return on Equity-54.80% Return on Assets-43.87%Miscellaneous Employees71 Outstanding Shares29,678,000Market Cap$265.02 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $8.93 -0.32 (-3.46 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CNCE News and Ratings via Email Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter. Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions How has Concert Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)? Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CNCE stock has increased by 6.9% and is now trading at $8.93. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Concert Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Concert Pharmaceuticals. When is Concert Pharmaceuticals' next earnings date? Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Concert Pharmaceuticals. How were Concert Pharmaceuticals' earnings last quarter? Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.41) EPS for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.28. The biotechnology company had revenue of $6.39 million for the quarter, compared to the consensus estimate of $0.01 million. Concert Pharmaceuticals had a negative net margin of 1,108.62% and a negative return on equity of 54.80%. View Concert Pharmaceuticals' earnings history. What price target have analysts set for CNCE? 7 Wall Street analysts have issued 12 month target prices for Concert Pharmaceuticals' shares. Their forecasts range from $10.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $19.50 in the next year. This suggests a possible upside of 118.4% from the stock's current price. View analysts' price targets for Concert Pharmaceuticals. Who are some of Concert Pharmaceuticals' key competitors? Some companies that are related to Concert Pharmaceuticals include Esperion Therapeutics (ESPR), Nabriva Therapeutics (NBRV), Athenex (ATNX), Rhythm Pharmaceuticals (RYTM), Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH), Nkarta (NKTX), Arcturus Therapeutics (ARCT), Zogenix (ZGNX), BioXcel Therapeutics (BTAI), Arvinas (ARVN), I-Mab (ARQT), Retrophin (RTRX), Constellation Pharmaceuticals (CNST) and Gossamer Bio (GOSS). View all competitors. What other stocks do shareholders of Concert Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger Biopharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Intel (INTC), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Pfizer (PFE) and TG Therapeutics (TGTX). Who are Concert Pharmaceuticals' key executives? Concert Pharmaceuticals' management team includes the following people: Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)Ms. Nancy Stuart, Chief Operating Officer (Age 61)Dr. James V. Cassella, Chief Devel. Officer (Age 64)Mr. Marc A. Becker, Chief Financial Officer (Age 47) What is Concert Pharmaceuticals' stock symbol? Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE." Who are Concert Pharmaceuticals' major shareholders? Concert Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (6.29%), Ingalls & Snyder LLC (4.66%), Alyeska Investment Group L.P. (1.69%), Nuveen Asset Management LLC (1.14%), Prudential Financial Inc. (1.04%) and Jacobs Levy Equity Management Inc. (0.78%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Thomas G Auchincloss. View institutional ownership trends for Concert Pharmaceuticals. Which major investors are selling Concert Pharmaceuticals stock? CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Prudential Financial Inc., California Public Employees Retirement System, Man Group plc, Alps Advisors Inc., and Jacobs Levy Equity Management Inc.. View insider buying and selling activity for Concert Pharmaceuticals. Which major investors are buying Concert Pharmaceuticals stock? CNCE stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Alyeska Investment Group L.P., Bessemer Group Inc., Dupont Capital Management Corp, Russell Investments Group Ltd., SG Americas Securities LLC, Hancock Whitney Corp, and Steward Partners Investment Advisory LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich, and Thomas G Auchincloss. View insider buying and selling activity for Concert Pharmaceuticals. How do I buy shares of Concert Pharmaceuticals? Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Concert Pharmaceuticals' stock price today? One share of CNCE stock can currently be purchased for approximately $8.93. How big of a company is Concert Pharmaceuticals? Concert Pharmaceuticals has a market capitalization of $265.02 million and generates $1.08 million in revenue each year. The biotechnology company earns $-78,170,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe. What is Concert Pharmaceuticals' official website? The official website for Concert Pharmaceuticals is www.concertpharma.com. How can I contact Concert Pharmaceuticals? Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
